Vincerx Pharma, Inc. Common Stock Cash Flow Conversion Efficiency
Vincerx Pharma, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Vincerx Pharma, Inc. Common Stock (VINC) has a cash flow conversion efficiency ratio of -2.156x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.45 Million) by net assets ($2.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Vincerx Pharma, Inc. Common Stock (2019–2024)
Cash flow conversion efficiency of Vincerx Pharma, Inc. Common Stock from 2019 to 2024. This chart illustrates how Vincerx Pharma, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View VINC stock price for real-time trading data and today's change.
Vincerx Pharma, Inc. Common Stock Cash Flow Conversion Ratio Explained
Vincerx Pharma, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Vincerx Pharma, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vincerx Pharma, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see VINC stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kasikornbank Public Company Limited
F:TFBF
|
0.050x |
|
Konan Technology Inc.
KQ:402030
|
N/A |
|
The Siam Cement Public Company Limited
F:TCM1
|
0.018x |
|
Walker Crips Group PLC
LSE:WCW
|
-0.456x |
|
Jangada Mines Plc
LSE:JAN
|
-0.090x |
|
Tower Resources plc
LSE:TRP
|
0.068x |
|
Touchstar plc
LSE:TST
|
0.662x |
|
Marechale Capital Plc
LSE:MAC
|
-0.059x |
Annual Cash Flow Conversion Efficiency for Vincerx Pharma, Inc. Common Stock (2019–2024)
The table below shows the annual cash flow conversion efficiency of Vincerx Pharma, Inc. Common Stock from 2019 to 2024. Review how financially flexible is Vincerx Pharma, Inc. Common Stock to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $2.72 Million | $-26.13 Million | -9.591x | -166.07% |
| 2023-12-31 | $11.22 Million | $-40.45 Million | -3.605x | -188.29% |
| 2022-12-31 | $47.67 Million | $-59.60 Million | -1.250x | -275.55% |
| 2021-12-31 | $100.32 Million | $-33.40 Million | -0.333x | -742.78% |
| 2020-12-31 | $57.69 Million | $-2.28 Million | -0.040x | -104.85% |
| 2019-12-31 | $-43.00K | $-35.00K | 0.814x | -- |
About Vincerx Pharma, Inc. Common Stock
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and prov… Read more